Retinoblastoma (Eye Cancer)

Retinoblastoma (Eye Cancer)

News & Stories

woman with dog smiling
Health Lab

Patient with retinitis pigmentosa receives new hope at Kellogg’s low vision clinic

Retinitis pigmentosa can lead to vision loss, but DNA testing, inherited retinal disease research and AI glasses offer new hope.
presentation on stage with slideshow up
Health Lab

Medical students develop novel technological solutions for unmet patient needs

University of Michigan medical students showcased AI-driven healthcare innovation projects focused on melanoma support, transplant recovery and primary care access.
Close up of a hazel green eye
Health Lab

A new clue for aging eyes

Struggling to read more than six lines on an eye chart with fading letters may serve as a visual “yellow light” for older adults—raising red flags that routine exams sometimes fail to detect.
Susan Lane, wearing glasses and a dress with blue, red, black, and purple brushstroke designs, stands next to Alan Sugar, who is wearing glasses and a grey blazer with a blue tie. They are standing in a shaded courtyard area with shrubs and a brick wall behind them.
Philanthropy News

Susan J. Lane: Gratitude and Giving

Susan Lane has made a transformational gift to the Department of Ophthalmology and Visual Sciences at Michigan Medicine to support corneal research and patient education.
person putting contacts on up close to mirror
Health Lab

Improving eye comfort in patients who wear contact lenses

Common difficulties include persistent discomfort, dry eyes, small bumps on the eye surface called corneal infiltrates and inflammation of the upper eyelid. Karen DeLoss, clinical associate professor of ophthalmology and visual sciences at U-M Health discusses how contact lenses work, types of lenses available and treatment options for patients who struggle with wearing them.
eye drawing blue yellow highlight
Health Lab

Adult stem cells show therapeutic promise in treating vision loss from macular degeneration

Researchers used retinal pigment epithelial stem cells derived from adult postmortem eye tissue in a phase 1/2a clinical trial. This is the first treatment to show promise for age-related macular degeneration or AMD.